Celator® Pharmaceuticals to Host Analyst and Investor Day on July 16, 2015

Jul 07, 2015, 08:00 ET from Celator Pharmaceuticals, Inc.

EWING, N.J., July 7, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the company will host an Analyst and Investor Day on Thursday, July 16, 2015, from 9:00am to 12:00pm ET at the Omni Berkshire Place Hotel in New York City. A live webcast will be available on the investor section of Celator's website at www.celatorpharma.com. An archived replay of the webcast will be available on the website for 90 days after the event.

Scott Jackson, Chief Executive Officer, and other members of Celator's senior management team will discuss an overview of the company's growth strategy, its lead product candidate, CPX-351, and its proprietary CombiPlex® technology platform. In addition, distinguished thought leaders are scheduled to participate, including:

  • Gail Roboz, M.D., Associate Professor of Medicine and Director of the Leukemia Program at Cornell University – Weill Medical College and NewYork-Presbyterian Hospital;
  • Bruno C. Medeiros, M.D., Associate Professor of Medicine, Director of the Stanford Acute Leukemia Clinical Research Program, Director of the Stanford Hospital Hematology Inpatient Service at Stanford University School of Medicine; and
  • Anthony Tolcher, M.D., Director of Clinical Research, South Texas Accelerated Research Therapeutics.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a late-stage clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.  CombiPlex® addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor.  Celator's pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. The company is advancing the CombiPlex platform and broadening its application to include molecularly targeted therapies and epigenetic modulators.

For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and development programs, future results, the efficacy and commercial potential of our drug candidates, and performance and achievements to differ significantly from those expressed or implied by the forward-looking statements. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014 and other filings by the company with the U.S. Securities and Exchange Commission.

 

 

SOURCE Celator Pharmaceuticals, Inc.



RELATED LINKS

http://www.celatorpharma.com